A two-cohort phase I/II trial of PTK787 and pemetrexed with or without cisplatin in patients with advanced non-small cell lung cancers and malignant pleural mesotheliomas.

Trial Profile

A two-cohort phase I/II trial of PTK787 and pemetrexed with or without cisplatin in patients with advanced non-small cell lung cancers and malignant pleural mesotheliomas.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2012

At a glance

  • Drugs Vatalanib (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Mar 2012 Planned End Date changed from 1 Sep 2006 to 1 Aug 2008 as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top